Åke Borg

Search results

• 2007

  Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers

  Elsakov, P., Foretova, L., Goetz, P., de Groot, J. W. B., van der Graaf, W. T. A., Guler, G., Huebner, K., Haites, N. E., Hamann, U., Ho, J., Imyanitov, E. N., Irmejs, A., Purkalne, G., Bitina, M., Gardovskis, A., Gardovskis, J., Kirova, Y. M., Fourquet, A., Pierga, J.-Y. & Stoppa-Lyonnet, D. & 25 others, Larizza, L., Lips, C. J. M., Loman, N., Borg, Å., Moller, P., Olsson, H., Park, J.-G., Radulovic, S., Brankovic-Magic, M., Rajkumar, T., Razis, E., Yannoukakos, D., Schmitt, F., Schmutzler, R., Simmonds, P. D., Eccles, D., Smeltzer, J., Silberstein, P. T., Lynch, H., Weber, W., Willemse, P. H. B., Sijmons, R. H., Wysocki, P. J., Zajac, V. & Shu, Z., 2007, In: Hereditary Cancer in Clinical Practice. 5, 3, p. 119-143

  Research output: Contribution to journal › Debate/Note/Editorial